DDInter1570 DDInter1293
Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities. Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms. With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.
Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML.
Ranolazine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Nilotinib
Ranolazine {u} (Compound) upregulates {v} (Gene) DENND2D
DENND2D {u} (Gene) is upregulated by {v} (Compound) Nilotinib
Ranolazine {u} (Compound) downregulates {v} (Gene) MRPS16
MRPS16 {u} (Gene) is downregulated by {v} (Compound) Nilotinib
Ranolazine {u} (Compound) causes {v} (Side Effect) Anxiety
Anxiety {u} (Side Effect) is caused by {v} (Compound) Nilotinib
Ranolazine {u} (Compound) resembles {v} (Compound) Carvedilol
Carvedilol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Ranolazine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ponatinib
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Ranolazine {u} (Compound) upregulates {v} (Gene) DENND2D
DENND2D {u} (Gene) regulates {v} (Gene) MAL
MAL {u} (Gene) is upregulated by {v} (Compound) Nilotinib
Ranolazine {u} (Compound) downregulates {v} (Gene) MRPS16
MRPS16 {u} (Gene) is downregulated by {v} (Compound) Ponatinib
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Ranolazine {u} (Compound) causes {v} (Side Effect) Anxiety
Anxiety {u} (Side Effect) is caused by {v} (Compound) Raltegravir
Raltegravir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Nilotinib
Ranolazine {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Ponatinib
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Ranolazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nilotinib (Compound)
Ranolazine (Compound) upregulates DENND2D (Gene) and DENND2D (Gene) is upregulated by Nilotinib (Compound)
Ranolazine (Compound) downregulates MRPS16 (Gene) and MRPS16 (Gene) is downregulated by Nilotinib (Compound)
Ranolazine (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Nilotinib (Compound)
Ranolazine (Compound) resembles Carvedilol (Compound) and Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Ranolazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ponatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Ranolazine (Compound) upregulates DENND2D (Gene) and DENND2D (Gene) regulates MAL (Gene) and MAL (Gene) is upregulated by Nilotinib (Compound)
Ranolazine (Compound) downregulates MRPS16 (Gene) and MRPS16 (Gene) is downregulated by Ponatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Ranolazine (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Raltegravir (Compound) and Raltegravir may cause a minor interaction that can limit clinical effects when taken with Nilotinib
Ranolazine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ponatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib